Cat. No. 2691
Alternative Name: RS 10085
Chemical Name: 2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)
Biological ActivityAngiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed in the liver to the active metabolite moexiprilat (IC50 values are 2.1 and 2700 nM for moexiprilat and moexipril respectively). Antihypertensive; decreases mean blood pressure in the spontaneous hypertensive rat (SHR). Also blocks degradation of bradykinin into inactive metabolites.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Edling et al (1995) Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J.Pharmacol.Exp.Ther. 275 854. PMID: 7473177.
Friehe and Ney (1997) Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneim.-Forsch. 47 132.
Chrysant and Chrysant (2004) Pharmacological and clinical profile of moexipril: a concise review. J.Clin.Pharmacol. 44 827. PMID: 15286086.
If you know of a relevant citation for this product please let us know.
Keywords: Moexipril hydrochloride, supplier, Angiotensin-converting, enzyme, ACE, inhibitors, Proteinases, Proteases, RS10085
Find multiple products by catalog number
New Products in this Area
Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitorAprotinin
Competitive serine protease inhibitorTCID
Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor2-MPPA
Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailableE 64
Potent and irreversible cysteine protease inhibitorAEBSF
Broad spectrum, irreversible inhibitor of serine proteasesTC-E 5006
γ-secretase modulator; reduces Aβ42 levelsPTIQ
Potent MMP-3 expression inhibitor; neuroprotective
December 6 - 10, 2014
Booth Number: 515